Capivasertib China PK study

Study identifier:D3614C00002

ClinicalTrials.gov identifier:NCT04742036

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Capivasertib Monotherapy and in Combination with Paclitaxel in Chinese Patients with Advanced Solid Tumours.

Medical condition

Advanced Solid Tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

Capivasertib, Paclitaxel

Sex

All

Actual Enrollment

16

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 22 Feb 2021
Primary Completion Date: 29 Jul 2022
Study Completion Date: 29 Jul 2022

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria